BCLI - Brainstorm Cell Therapeutics Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
4.30
-0.11 (-2.49%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close4.41
Open4.39
Bid0.00 x 800
Ask0.00 x 1100
Day's Range4.25 - 4.43
52 Week Range2.88 - 5.35
Volume56,276
Avg. Volume138,078
Market Cap87.073M
Beta2.35
PE Ratio (TTM)N/A
EPS (TTM)-0.29
Earnings DateAug 13, 2018 - Aug 17, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
Trade prices are not sourced from all markets
  • Forbes6 days ago

    Biotech Executives Fret Over Hassles And Uncertainties Of 'Right To Try'

    ALS patient Frank Mongiello, center, shown here with his wife and daughter during a news conference following the passage of the Right to Try Act, is among the many patients hoping to access experimental treatments under the new law. At last week’s annual convention of the Biotechnology Innovation Organization (BIO) in Boston, FDA Commissioner Scott Gottlieb said during an on-stage interview that his agency has recently initiated a formal process for handling “Right to Try,” the law passed May 30 that allows terminally ill patients to use experimental drugs that have not yet been approved. Indeed, Gottlieb himself was the target of one such executive.

  • Zacks Small Cap Research8 days ago

    BCLI: Determining Path Forward Following “Right to Try”; Warrant Exercise Raises $12.3M

    On June 7, 2018, BrainStorm Cell Therapeutics (BCLI) held a conference call to engage with ALS patients and caregivers following the signing of the “Right-to-Try” legislation by President Trump. The law allows those with a terminal illness to seek out treatments from pharmaceutical companies that have not yet been approved by the FDA. Before the passage of the “Right-to-Try” law, patients could petition the FDA for access to an experimental treatment through the “expanded access program”.

  • PR Newswire12 days ago

    BrainStorm Announces Exercise of Warrants Resulting in Cash Proceeds of ~$12.3 Million at $5 Share

    NEW YORK and PETACH TIKVA, Israel , June 7, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today ...

  • Should You Worry About Brainstorm Cell Therapeutics Inc’s (NASDAQ:BCLI) CEO Pay?
    Simply Wall St.16 days ago

    Should You Worry About Brainstorm Cell Therapeutics Inc’s (NASDAQ:BCLI) CEO Pay?

    Chaim Lebovits is the CEO of Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI), which has recently grown to a market capitalization of US$91.73M. Recognizing whether CEO incentives are aligned with shareholders isRead More...

  • PR Newswire18 days ago

    BrainStorm to Host Call Following President Trump's Citing of Company's ALS Treatment During "Right-to-Try" Bill Signing

    Conference call and live webcast on June 7th at 8:15am EDT NEW YORK and PETACH TIKVAH, Israel, June 1, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult ...

  • PR Newswire20 days ago

    BrainStorm Cell Therapeutics to Provide Corporate Update at the BIO International Convention

    NEW YORK and PETACH TIKVAH, Israel , May 30, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced ...

  • PR Newswire25 days ago

    BrainStorm Cell Therapeutics Issues Statement on "Right to Try" Legislation

    NEW YORK and PETACH TIKVAH, Israel, May 25, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today issues a statement following Congress passing the Federal "Right-to-Try" bill. The "Right-to-Try" bill will enable terminally ill patients who do not meet clinical trial criteria to seek out experimental therapies that do not yet have approval by the US Food and Drug Administration (FDA). Chaim Lebovits, president and chief executive officer of BrainStorm Cell Therapeutics, stated, "BrainStorm understands the serious unmet medical need and urgency of people living with ALS.

  • Zacks Small Cap Researchlast month

    BCLI: Enrollment in Phase 3 Trial of NurOwn® Continuing on Schedule

    BrainStorm Cell Therapeutics, Inc. (BCLI) is continuing to enroll patients in the Phase 3 clinical trial of NurOwn® (NCT03280056) for the treatment of amyotrophic lateral sclerosis (ALS). Last year, BrainStorm received a $16 million grant from the California Institute for Regenerative Medicine (CIRM) to help fund the Phase 3 clinical trial of NurOwn®.

  • What Should Investors Know About Brainstorm Cell Therapeutics Inc’s (NASDAQ:BCLI) Future?
    Simply Wall St.last month

    What Should Investors Know About Brainstorm Cell Therapeutics Inc’s (NASDAQ:BCLI) Future?

    The latest earnings announcement Brainstorm Cell Therapeutics Inc’s (NASDAQ:BCLI) released in December 2017 revealed company earnings became less negative compared to the previous year’s level – great news for investorsRead More...

  • PR Newswirelast month

    BrainStorm Announces First Quarter 2018 Financial Results and Provides Corporate and Clinical Highlights

    Call Today and Webcast @ 8:30am Eastern Time Today NEW YORK, N.Y. and PETACH TIKVAH, Israel , May 14, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult ...

  • ACCESSWIRElast month

    Brainstorm Cell Therapeutics Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 14, 2018 / Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 14, 2018 at 8:30:00 AM ...

  • PR Newswirelast month

    BrainStorm CEO to Present at World Advanced Therapy and Regenerative Medicine Congress in London

    NEW YORK and PETACH TIKVAH, Israel , May 9, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced ...

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: Cel-Sci Corporation and Brainstorm Cell Therapeutics

    NEW YORK, NY / ACCESSWIRE / May 8, 2018 / A strong performance by the energy sector lifted U.S. markets higher for the second consecutive session Monday as oil prices topped $70 a barrel. Investor attention ...

  • PR Newswirelast month

    Brainstorm to Announce First Quarter Financial Results and Provide Corporate Update on Monday, May 14

    Conference Call and Live Webcast at 8:30am Eastern Time NEW YORK and PETACH TIKVAH, Israel , May 8, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem ...

  • PR Newswire2 months ago

    BrainStorm Cell Therapeutics to Participate in Movement Disorder Panel at the Neurotech Investing and Partnering Conference

    NEW YORK and PETACH TIKVAH, Israel , May 1, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today ...

  • PR Newswire2 months ago

    BrainStorm Cell Therapeutics to Present at ARM's 6th Annual Cell & Gene Therapy Investor Day, April 17 in New York

    NEW YORK and PETACH TIKVAH, Israel , April 11, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, ...

  • PR Newswire3 months ago

    BrainStorm Cell Therapeutics' Phase 3 Trial of NurOwn® in ALS Now Open to Canadian Patients

    NEW YORK and PETACH TIKVAH, Israel, March 28, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announces that it has amended  the protocol of its Phase 3 clinical trial of NurOwn® for the treatment of amyotrophic lateral sclerosis (ALS). Per the protocol amendment, Canada-based ALS patients may now enroll in the ongoing Phase 3 NurOwn clinical trial. "We are pleased to open enrollment to Canada-based ALS patients," said Chaim Lebovits, president and chief executive officer of BrainStorm Cell Therapeutics.  "Although there are thousands of patients worldwide with ALS, we initially designed the Phase 3 trial to enroll U.S.-based patients only, primarily to make it easier for patient follow-up visits at the six U.S. clinical sites.  However, due to an outpouring of inquiry and support from Canadian patients wanting to enroll in the trial, we filed an amendment with the FDA to allow Canada-based ALS patients to participate.

  • PR Newswire3 months ago

    BrainStorm Appoints Two Leading Thought Leaders in the Fields of Neuroscience and Regenerative Medicine to its Scientific Advisory Board

    HACKENSACK, N.J. and PETACH TIKVAH, Israel, March 21, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced the appointments of Stanley H. Appel, M.D., and Amit Bar-Or, M.D., to its scientific advisory board (SAB). Dr. Appel and Dr. Bar-Or are joining Jerold Chun, M.D., Ph.D., who was recently appointed chair of BrainStorm's SAB. "We are extremely pleased and honored to have two of the leading thought leaders in the fields of neuroscience and regenerative medicine join our scientific advisory board," said Chaim Lebovits, president and chief executive officer of BrainStorm Cell Therapeutics.

  • PR Newswire3 months ago

    BrainStorm Cell Therapeutics to Present at the BIO Asia International Conference and the Wall Street Investor Forum

    HACKENSACK, N.J. and PETACH TIKVAH, Israel, March 15, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, ...

  • Zacks Small Cap Research3 months ago

    BCLI: Phase 3 Trial in ALS Enrolling Patients

    BrainStorm Cell Therapeutics, Inc. (BCLI) has enrolled the first patients in the Phase 3 clinical trial of NurOwn® (NCT03280056) for the treatment of amyotrophic lateral sclerosis (ALS). Cells will be extracted from each patient one time prior to treatment, with all administrations of NurOwn® derived from the same extraction of cells thanks to a cryopreservation process developed for long-term storage of mesenchymal stem cells (MSC). The company is focusing the trial on faster-progressing ALS patients since these patients demonstrated superior outcomes in the Phase 2 trial of NurOwn®.

  • PR Newswire3 months ago

    BrainStorm Announces Formation of Scientific Advisory Board and Appoints Neuroscientist Jerold Chun, M.D., Ph.D., to Chair

    HACKENSACK, N.J. and PETACH TIKVAH, Israel, March 12, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today the formation of its Scientific Advisory Board (SAB) and the appointment of Jerold Chun, M.D., Ph.D., to Chair. Chun is an acclaimed neuroscientist and professor at Sanford Burnham Prebys Medical Discovery Institute with decades of expertise in degenerative disease research and neuroscience drug development. The SAB at BrainStorm will be composed of renowned scientists and clinical experts and will advise BrainStorm's management team on scientific matters such as research, clinical trials and drug development.

  • ACCESSWIRE3 months ago

    Brainstorm Cell Therapeutics Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 8, 2018 / Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 8, 2018 at 8:30 AM ...

  • PR Newswire3 months ago

    BrainStorm Announces Operational Highlights and Financial Results for the Year Ended December 31, 2017

    Conference Call and Webcast @ 8:30 a.m. Eastern Time Today NEW YORK and PETACH TIKVAH, Israel , March 8, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult ...